We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 410

Court dismisses motion for Confidentiality Order
  • Borden Ladner Gervais LLP
  • Canada
  • May 18 2017

The Court dismissed Teva's motion for a confidentiality order. The underlying proceeding is an action by Teva to recover from Janssen and others


Reasonable Royalty and Accounting of Profits Determinations Made
  • Borden Ladner Gervais LLP
  • Canada
  • May 10 2017

In a previous decision, which was affirmed, the Court found that Dow's patent was valid and infringed by Nova. Once a finding of liability was made


Court Refuses Motion to Amend Brought After the Commencement of the Quantification Trial
  • Borden Ladner Gervais LLP
  • Canada
  • May 10 2017

This decision concerned the quantification phase following the liability determination, which found AstraZeneca's patent valid and infringed. Apotex


Federal Court Holds That a Request to Find a Dead Patent Application in Good Standing Must Fail
  • Borden Ladner Gervais LLP
  • Canada
  • May 10 2017

The Federal Court has refused to declare that an application is in good standing after the applicants or their agents failed to reply to a requisition


Findings Made in Section 8 Case to Allow Determination of Quantum of Damages
  • Borden Ladner Gervais LLP
  • Canada
  • May 10 2017

In this case, Teva is seeking compensation pursuant to s. 8 of the NOC Regulations for having been prevented from coming to market with its generic


Court of Appeal Grants Appeal as it Relates to Duty to Mitigate
  • Borden Ladner Gervais LLP
  • Canada
  • April 19 2017

In this decision, the Court of Appeal was considering an appeal by Apotex of various findings of the Court relating to its action seeking damages from


Court of Appeal Dismisses Appeal for Different Reasons and Provides Review of the Obvious to Try Test
  • Borden Ladner Gervais LLP
  • Canada
  • April 19 2017

The Court of Appeal dismissed Bristol-Myers Squibb's appeal from the Trial Judge's decision refusing its application for a writ of prohibition on the


Apotex Granted Leave to Expand Scope of Evidence Available to Prove its NIA Plea
  • Borden Ladner Gervais LLP
  • Canada
  • April 12 2017

In this recently reported decision, the Court granted Apotex leave to deliver Fresh as Amended Responding Statement of Issues for the reference into


Order of prohibition dismissed in respect of two patents listed against dasatinib
  • Borden Ladner Gervais LLP
  • Canada
  • April 6 2017

The Court dismissed Bristol Myers Squibb's application for an order prohibiting the Minister from issuing an NOC to Apotex for its generic version of


Court provides method for assessing quantum of Teva's section 8 damages
  • Borden Ladner Gervais LLP
  • Canada
  • April 6 2017

In this case, the parties had asked the Court for specific rulings and guidance in calculating Teva's section 8 damages. The parties were in agreement